-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 RToTbEmJ1cLuIRApBI7WwQFdq4dubTxI7rEmQhEapGH2aPdFhh0cncyr/hWPahzW
 4rPc8+kWMxTgzWooSXBB6Q==

<SEC-DOCUMENT>0000012208-09-000060.txt : 20090804
<SEC-HEADER>0000012208-09-000060.hdr.sgml : 20090804
<ACCEPTANCE-DATETIME>20090804164318
ACCESSION NUMBER:		0000012208-09-000060
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20090630
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090804
DATE AS OF CHANGE:		20090804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO RAD LABORATORIES INC
		CENTRAL INDEX KEY:			0000012208
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				941381833
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-07928
		FILM NUMBER:		09984105

	BUSINESS ADDRESS:	
		STREET 1:		1000 ALFRED NOBEL DR
		CITY:			HERCULES
		STATE:			CA
		ZIP:			94547
		BUSINESS PHONE:		5107247000
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>b8kcover6302009.htm
<DESCRIPTION>FORM 8-K 06/30/2009
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>UNITED STATES</TITLE>
<META NAME="author" CONTENT="Tom Brida">
<META NAME="date" CONTENT="04/21/2008">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:643.2px"><P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><B>UNITED STATES</B></P>
<P style="margin:0px" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="margin:0px" align=center><B>Washington, D.C. 20549</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="line-height:16pt; margin:0px; font-size:14pt" align=center><B>FORM 8-K</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:8pt; margin:0px"><BR></P>
<P style="margin:0px" align=center><B>CURRENT REPORT</B></P>
<P style="line-height:10pt; margin:0px; font-size:8pt" align=center><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px" align=center><B>Date of Report: August 4, 2009</B></P>
<P style="line-height:10pt; margin:0px; font-size:8pt" align=center><B>(Date of earliest event reported)</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="line-height:9pt; margin:0px"><BR></P>
<P style="line-height:8pt; margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px; font-size:14pt" align=center><B>BIO-RAD LABORATORIES, INC.</B></P>
<P style="line-height:10pt; margin:0px; font-size:8pt" align=center><B>(Exact name of registrant as specified in its charter)</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:9pt; margin:0px"><BR></P>
<P style="margin:0px" align=center><B>Commission File Number: 1-7928</B></P>
<P style="margin:0px; font-size:8pt">&nbsp;</P>
</DIV><TABLE style="font-size:10pt" cellspacing=0><TR height=0 style="font-size:0"><TD width=360></TD><TD width=7.133></TD><TD width=352.8></TD></TR>
<TR><TD width=360><P style="margin:0px; font-size:8pt">&nbsp;</P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:8pt">&nbsp;</P>
</TD><TD width=352.8><P style="margin:0px; font-size:8pt">&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=360><P style="margin:0px" align=center><B>Delaware</B></P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:8pt">&nbsp;</P>
</TD><TD valign=top width=352.8><P style="margin:0px" align=center><B>94-1381833</B></P>
</TD></TR>
<TR><TD valign=top width=360><P style="line-height:10pt; margin:0px; font-size:8pt" align=center><B>(State or other jurisdiction of</B></P>
<P style="line-height:10pt; margin:0px; font-size:8pt" align=center><B>incorporation or organization)</B></P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:8pt">&nbsp;</P>
</TD><TD valign=top width=352.8><P style="line-height:10pt; margin:0px; font-size:8pt" align=center><B>(I.R.S. Employer</B></P>
<P style="line-height:10pt; margin:0px; font-size:8pt" align=center><B>Identification No.)</B></P>
</TD></TR>
</TABLE>
<DIV style="width:643.2px"><P style="line-height:8pt; margin:0px"><BR></P>
<P style="line-height:8pt; margin:0px; font-size:8pt">&nbsp;</P>
<P style="margin:0px" align=center><B>1000 Alfred Nobel Dr.</B></P>
<P style="margin:0px" align=center><B>Hercules, California 94547</B></P>
<P style="line-height:10pt; margin:0px; font-size:8pt" align=center><B>(Address of principal executive offices, including zip code)</B></P>
<P style="margin:0px; font-size:8pt">&nbsp;</P>
<P style="margin:0px" align=center><B>(510) 724-7000</B></P>
<P style="line-height:10pt; margin:0px; font-size:8pt" align=center><B>(Registrant&#146;s telephone number, including area code)</B></P>
<P style="margin:0px; font-size:8pt">&nbsp;</P>
<P style="line-height:8pt; margin:0px"><BR></P>
<P style="line-height:8pt; margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:8pt; margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:10pt; margin:0px; font-size:8pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>
<P style="margin:0px; font-size:8pt">&nbsp;</P>
<TABLE style="font-size:10pt" cellspacing=0><TR height=0 style="font-size:0"><TD width=28.8></TD><TD width=562.733></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:10pt; margin:0px; font-family:Wingdings; font-size:8pt">&#168;</P>
</TD><TD valign=top width=562.733><P style="line-height:10pt; margin:0px; font-size:8pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:8pt">&nbsp;</P>
<TABLE style="font-size:10pt" cellspacing=0><TR height=0 style="font-size:0"><TD width=28.8></TD><TD width=565.6></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:10pt; margin:0px; font-family:Wingdings; font-size:8pt">&#168;</P>
</TD><TD valign=top width=565.6><P style="line-height:10pt; margin:0px; font-size:8pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:8pt">&nbsp;</P>
</DIV><TABLE style="font-size:10pt" cellspacing=0><TR height=0 style="font-size:0"><TD width=28.8></TD><TD width=616.267></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:10pt; margin:0px; font-family:Wingdings; font-size:8pt">&#168;</P>
</TD><TD valign=top width=616.267><P style="line-height:10pt; margin:0px; font-size:8pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>
</TD></TR>
</TABLE>
<DIV style="width:643.2px"><P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:8pt">&nbsp;</P>
</DIV><TABLE style="font-size:10pt" cellspacing=0><TR height=0 style="font-size:0"><TD width=28.8></TD><TD width=615></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:10pt; margin:0px; font-family:Wingdings; font-size:8pt">&#168;</P>
</TD><TD valign=top width=615><P style="line-height:10pt; margin:0px; font-size:8pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>
</TD></TR>
</TABLE>
<DIV style="width:643.2px"><P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px; page-break-before:always"><B>&nbsp;</B></P>
<P style="margin:0px">&nbsp;</P>
<TABLE style="font-size:10pt" cellspacing=0><TR height=0 style="font-size:0"><TD width=83.333></TD><TD width=285.933></TD></TR>
<TR><TD valign=top width=83.333><P style="margin:0px" align=justify><B>ITEM 2.02</B></P>
</TD><TD valign=top width=285.933><P style="margin:0px"><B>Results of Operations and Financial Condition</B></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px">On August 4, 2009, Bio-Rad Laboratories, Inc. announced its results of operations and financial condition as of and for the quarter ended June 30, 2009. &nbsp;A copy of the press release is furnished as Exhibit 99.1 to this report.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px">In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be &#147;filed&#148; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. </P>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR height=0 style="font-size:0"><TD width=83.333></TD><TD width=492.667></TD></TR>
<TR><TD valign=top width=83.333><P style="margin:0px"><B>ITEM 9.01</B></P>
</TD><TD valign=top width=492.667><P style="margin:0px"><B>Financial Statements and Exhibits</B></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:10pt" cellspacing=0><TR height=0 style="font-size:0"><TD width=60></TD><TD width=24></TD><TD width=497.533></TD></TR>
<TR><TD width=60><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=24><P style="margin:0px">&nbsp;</P>
</TD><TD width=497.533><P style="margin:0px">&nbsp;</P>
</TD></TR>
<TR><TD style="border-bottom:1px solid #000000" valign=bottom width=60><P style="margin:0px"><B>Exhibit</B></P>
<P style="margin:0px"><B>Number&nbsp;</B></P>
</TD><TD valign=bottom width=24><P style="margin:0px">&nbsp;</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=497.533><P style="margin:0px"><BR></P>
<P style="margin:0px"><B>Description</B></P>
</TD></TR>
<TR><TD valign=top width=60><P style="margin-top:2.2px; margin-bottom:0px" align=right>99.1&nbsp;</P>
</TD><TD valign=bottom width=24><P style="margin-top:2.2px; margin-bottom:0px">&nbsp;</P>
</TD><TD valign=bottom width=497.533><P style="margin-top:2.2px; margin-bottom:0px">Press release of Bio-Rad Laboratories, Inc. dated August 4, 2009</P>
</TD></TR>
</TABLE>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR>
<BR></P>
<P style="margin:0px; page-break-before:always" align=center><B>SIGNATURES</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0px">&nbsp;&nbsp;</P>
<TABLE style="font-size:10pt" cellspacing=0><TR height=0 style="font-size:0"><TD width=50.867></TD><TD width=136.333></TD><TD width=29.467></TD><TD width=29.467></TD><TD width=4></TD><TD width=253.867></TD></TR>
<TR><TD valign=top width=50.867><P>&nbsp;</P></TD><TD width=136.333><P>&nbsp;</P></TD><TD valign=top width=29.467><P>&nbsp;</P></TD><TD valign=top width=29.467><P>&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P>&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P>&nbsp;</P></TD><TD width=136.333><P>&nbsp;</P></TD><TD valign=top width=29.467><P>&nbsp;</P></TD><TD valign=top width=29.467><P>&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P>&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P>&nbsp;</P></TD><TD width=136.333><P>&nbsp;</P></TD><TD valign=top width=29.467><P>&nbsp;</P></TD><TD valign=top width=287.333 colspan=3><P style="margin:0px">BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=50.867><P>&nbsp;</P></TD><TD width=136.333><P>&nbsp;</P></TD><TD valign=top width=29.467><P>&nbsp;</P></TD><TD valign=top width=29.467><P>&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P>&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="margin:0px">Date:</P>
</TD><TD style="border-bottom:1px solid #000000" width=136.333><P style="margin:0px">August 4, 2009</P>
</TD><TD valign=top width=29.467><P>&nbsp;</P></TD><TD valign=top width=29.467><P style="margin:0px">By:</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=257.867 colspan=2><P style="margin:0px">/s/ Christine A. Tsingos</P>
</TD></TR>
<TR><TD valign=top width=50.867><P>&nbsp;</P></TD><TD valign=top width=136.333><P>&nbsp;</P></TD><TD valign=top width=29.467><P>&nbsp;</P></TD><TD valign=bottom width=29.467><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=4><P>&nbsp;</P></TD><TD valign=bottom width=253.867><P style="margin:0px">Christine A. Tsingos </P>
</TD></TR>
<TR><TD valign=top width=50.867><P>&nbsp;</P></TD><TD valign=top width=136.333><P>&nbsp;</P></TD><TD valign=top width=29.467><P>&nbsp;</P></TD><TD valign=bottom width=29.467><P>&nbsp;</P></TD><TD valign=bottom width=4><P>&nbsp;</P></TD><TD valign=bottom width=253.867><P style="margin:0px">Vice President, Chief Financial Officer</P>
</TD></TR>
<TR><TD valign=top width=50.867><P>&nbsp;</P></TD><TD valign=top width=136.333><P style="margin:0px">&nbsp;</P>
</TD><TD valign=top width=29.467><P>&nbsp;</P></TD><TD valign=bottom width=29.467><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=4><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=253.867><P>&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<A NAME="id_11"></A><A NAME="id_12"></A><P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><B>EXHIBIT INDEX</B></P>
<P style="margin:0px">&nbsp;</P>
<TABLE style="font-size:10pt" cellspacing=0 align=center><TR height=0 style="font-size:0"><TD width=34.2></TD><TD width=28.267></TD><TD width=513.533></TD></TR>
<TR><TD width=34.2><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=28.267><P style="margin:0px">&nbsp;</P>
</TD><TD width=513.533><P style="margin:0px">&nbsp;</P>
</TD></TR>
<TR><TD style="border-bottom:1px solid #000000" valign=bottom width=34.2><P style="line-height:9pt; margin:0px; font-size:7pt"><B>Exhibit</B></P>
<P style="line-height:9pt; margin:0px; font-size:7pt"><B>Number</B></P>
</TD><TD valign=bottom width=28.267><P style="margin:0px; font-size:7pt">&nbsp;</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=513.533><P style="line-height:9pt; margin:0px; font-size:7pt"><B>Description</B></P>
</TD></TR>
<TR><TD valign=top width=34.2><P style="margin:0px">99.1</P>
</TD><TD valign=bottom width=28.267><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=513.533><P style="margin:0px">Press release of Bio-Rad Laboratories, Inc. dated August 4, 2009</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
</DIV></BODY>
<!-- EDGAR Validation Code: B87F6DF4 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exh991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>PART 1 &#8211; FINANCIAL INFORMATION</TITLE>
<META NAME="author" CONTENT="Stephanie Trudrung">
<META NAME="date" CONTENT="11/06/2008">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:604.8px"><P style="line-height:14pt; margin:0px; font-size:12pt" align=right><B><U>Exhibit 99.1</U></B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:11pt; margin:0px; padding-right:43.2px; font-family:Arial; font-size:9pt"><B><I>FOR IMMEDIATE RELEASE</I></B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="line-height:14pt; margin:0px; padding-right:-24px; font-family:HelveticaNeueLT Std; font-size:12pt" align=center><B>BIO-RAD REPORTS SECOND-QUARTER </B></P>
<P style="line-height:14pt; margin:0px; padding-right:-24px; font-family:HelveticaNeueLT Std; font-size:12pt" align=center><B>CURRENCY- NEUTRAL REVENUE GROWTH OF 3.5 PERCENT</B></P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:11pt"><B>HERCULES, CA &#150; August 4, 2009 &#150;</B><FONT style="color:#0000FF"> </FONT>Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the second quarter ended June 30, 2009.</P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:11pt">Second-quarter reported revenues were $427.2 million,<FONT style="color:#0000FF"> </FONT>down 5.6% compared to<FONT style="color:#0000FF"> </FONT>$452.4 million<FONT style="color:#0000FF"> </FONT>reported for the second quarter of 2008.<FONT style="color:#0000FF"> </FONT>On a currency-neutral basis, quarterly revenues increased 3.5% compared to the same period last year. Net income attributable to Bio-Rad for the second quarter was $38.0 million, or $1.37 per share on a fully diluted basis,<FONT style="color:#0000FF"> </FONT>compared to $43.4 million or $1.57 per share, respectively, during the same period last year.<FONT style="color:#0000FF"> </FONT>Reflected in operating income are $5.5 million of amortization and purchase accounting adjustments for the second quarter of 2009 associated with the 2007 DiaMed acquisition. Second-quarter gross margin increased to 56.6% compared to 54.9% during the same quarter last year.
 </P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:11pt">Year-to-date revenues were $828.1 million, down 5.3% compared to the first two quarters in 2008. Adjusting for the impact of currency effects, revenue growth was 3.4%. Year-to-date net income attributable to Bio-Rad for 2009 was $68.2 million, or $2.47 per share on a fully diluted basis, compared to $69.9 million, or $2.54 per share, respectively, during the same period in 2008. &nbsp;&nbsp;</P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:11pt">&#147;We are encouraged by the strength we continue to see in many of our core markets despite currency headwinds and a weakened global economy, which have tempered our reported performance so far this year,&#148; said Norman Schwartz, Bio-Rad President and Chief Executive Officer. &#147;As the year progresses, we will remain focused on opportunities to improve our operational efficiencies as well as expand our business.&#148;</P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px; padding-right:43.2px; font-family:HelveticaNeueLT Std" align=center>(more)</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px; page-break-before:always"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:11pt; margin:0px; padding-right:43.2px; font-family:HelveticaNeueLT Std; font-size:9pt"><B><I>Bio-Rad Reports Second-Quarter 2009 Financial Results</I></B></P>
<P style="line-height:11pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:9pt"><B><I>Page 2</I></B></P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:11pt"><B>Life Science </B></P>
<P style="line-height:16pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:11pt">The Life Science segment net sales for the quarter were $149.7 million, down 7.4% or 0.4% on a currency-neutral basis, compared to the same period last year. Growth in the Life Science segment was negatively impacted by slowed research markets in both the U.S. and Europe, which reflect constraint and delays in spending by academic and biopharmaceutical customers.<FONT style="color:#0000FF"> </FONT>Performance during the quarter benefited from strong sales in protein function and gene expression products, in particular polymerase chain reaction (PCR) instruments and reagents. SsoFast<SUP>&#8482;</SUP> EvaGreen<SUP>&#174; </SUP>Supermix, the first member of Bio-Rad&#8217;s next-generation family of high-performance, real-time PCR reagents that was launched in April continues to gain customer acceptance.<FONT style="color:#0000FF"> </FONT></P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:11pt"><B>Clinical Diagnostics</B></P>
<P style="line-height:16pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:11pt">The Clinical Diagnostics segment reported net sales of $274.3 million for the quarter, down 4.6% compared to the second quarter in 2008. On a currency-neutral basis, sales for the segment increased 5.8%. This performance is the result of continued growth across all product lines, most notably blood virus testing products, microbiology, quality control products, and the Company&#146;s BioPlex<SUP>&#174; </SUP>2200 system. Shipments of blood virus test systems were particularly strong during the quarter across most regions. In June, the Company announced FDA clearance of two new multiplex infectious disease serology panels for use on the BioPlex 2200 system: the BioPlex ToRC IgG panel and the BioPlex HSV-1 &amp; HSV-2 IgG panel. The ToRC IgG kit simultaneously detects IgG class antibodies to <I>Toxoplasma gondii</I> (<I>T. gondii</I>), Rubella, and Cytomegalovirus (CMV). The HSV-1 &amp; HSV-2 IgG kit utilizes type-specific
 proteins to simultaneously detect and differentiate IgG class antibodies to the two most common herpes subtypes, HSV-1 and HSV-2. &nbsp;&nbsp;&nbsp;</P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:11pt">Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) August 4, 2009. Interested parties may access the call by dialing </P>
<P style="line-height:16pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:11pt">866-270-6057 (in the U.S.)<FONT style="color:#0000FF"> </FONT>or 617-213-8891 (international), access number 69361175.<FONT style="color:#0000FF"> </FONT></P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px; padding-right:43.2px; font-family:HelveticaNeueLT Std" align=center>(more)</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px; page-break-before:always"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:11pt; margin:0px; padding-right:43.2px; font-family:HelveticaNeueLT Std; font-size:9pt"><B><I>Bio-Rad Reports Second-Quarter 2009 Financial Results</I></B></P>
<P style="line-height:11pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:9pt"><B><I>Page 3</I></B></P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:11pt">The live webcast may also be accessed at http://www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.), or 617-801-6888 (international), access number 62221247 for seven days following the call, and the webcast can be accessed at http://www.bio-rad.com for 30 days.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:11pt"><B>About Bio-Rad</B></P>
<P style="line-height:16pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:11pt">Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The Company employs over 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, please visit www.bio-rad.com. </P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="margin:0px; font-family:HelveticaNeueLT Std"><I>This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, &#147;believe,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;will,&#148; &#147;intend,&#148; &#147;estimate,&#148; &#147;continue,&#148; or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the &#147;Risk Factors&#148; in the Company&#146;s public reports filed with the Securities and Exchange Commission, including the Company&#146;s most recent Annual Report on Form 10-K, Quarterly Rep
orts on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. &nbsp;Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements. </I></P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="line-height:16pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:11pt"><B>For more information contact:</B></P>
<P style="line-height:16pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:11pt">Christine Tsingos, Vice President and Chief Financial Officer, or</P>
<P style="line-height:16pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:11pt">Ron Hutton, Treasurer</P>
<P style="line-height:16pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:11pt">Bio-Rad Laboratories, Inc.</P>
<P style="line-height:16pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:11pt">510-724-7000</P>
<P style="line-height:16pt; margin:0px; font-family:HelveticaNeueLT Std; font-size:11pt">investor_relations@bio-rad.com</P>
<P style="line-height:16pt; margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px; page-break-before:always"><BR></P>
</DIV><TABLE style="font-size:10pt" cellspacing=0><TR height=0 style="font-size:0"><TD width=307.6></TD><TD width=67.2></TD><TD width=12></TD><TD width=67.2></TD><TD width=23.467></TD><TD width=67.2></TD><TD width=12.4></TD><TD width=68.933></TD></TR>
<TR><TD valign=top width=626 colspan=8><P>&nbsp;</P></TD></TR>
<TR><TD valign=top width=626 colspan=8><P style="margin:0px" align=center>BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=626 colspan=8><P style="margin:0px" align=center>Condensed Consolidated Statements of Income</P>
</TD></TR>
<TR><TD valign=top width=626 colspan=8><P style="margin:0px" align=center>(In thousands, except per share data)</P>
</TD></TR>
<TR><TD valign=top width=626 colspan=8><P style="margin:0px" align=center>(Unaudited)</P>
</TD></TR>
<TR><TD valign=top width=307.6><P>&nbsp;</P></TD><TD valign=top width=146.4 colspan=3><P>&nbsp;</P></TD><TD valign=top width=23.467><P>&nbsp;</P></TD><TD valign=top width=148.533 colspan=3><P>&nbsp;</P></TD></TR>
<TR><TD valign=top width=307.6><P>&nbsp;</P></TD><TD valign=top width=146.4 colspan=3><P style="margin:0px" align=center>Three Months Ended</P>
</TD><TD valign=top width=23.467><P>&nbsp;</P></TD><TD valign=top width=148.533 colspan=3><P style="margin:0px" align=center>Six Months Ended</P>
</TD></TR>
<TR><TD valign=top width=307.6><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=146.4 colspan=3><P style="margin:0px" align=center>June 30,</P>
</TD><TD valign=top width=23.467><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=148.533 colspan=3><P style="margin:0px" align=center>June 30,</P>
</TD></TR>
<TR><TD width=307.6><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=67.2><P style="margin:0px" align=right>2009&nbsp;</P>
</TD><TD width=12><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=67.2><P style="line-height:11pt; margin:0px" align=right>2008&nbsp;</P>
</TD><TD width=23.467><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=67.2><P style="line-height:11pt; margin:0px" align=right>2009&nbsp;</P>
</TD><TD width=12.4><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=68.933><P style="line-height:11pt; margin:0px" align=right>2008&nbsp;</P>
</TD></TR>
<TR><TD width=307.6><P>&nbsp;</P></TD><TD width=67.2><P>&nbsp;</P></TD><TD width=12><P>&nbsp;</P></TD><TD width=67.2><P>&nbsp;</P></TD><TD width=23.467><P>&nbsp;</P></TD><TD width=67.2><P>&nbsp;</P></TD><TD width=12.4><P>&nbsp;</P></TD><TD width=68.933><P>&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=307.6><P style="margin:0px">Net sales</P>
</TD><TD style="background-color:#CCFFCC" width=67.2><P style="margin:0px" align=right>$ &nbsp;427,183&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=12><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=67.2><P style="margin:0px" align=right>$ &nbsp;452,361&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=23.467><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=67.2><P style="margin:0px" align=right>$ &nbsp;828,116&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=12.4><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=68.933><P style="margin:0px" align=right>$ 874,558&nbsp;</P>
</TD></TR>
<TR><TD width=307.6><P style="margin:0px; text-indent:19.2px">Cost of goods sold</P>
</TD><TD style="border-bottom:1px solid #000000" width=67.2><P style="margin:0px" align=right>185,221&nbsp;</P>
</TD><TD width=12><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=67.2><P style="margin:0px" align=right>203,940&nbsp;</P>
</TD><TD width=23.467><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=67.2><P style="margin:0px" align=right>357,253&nbsp;</P>
</TD><TD width=12.4><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=68.933><P style="margin:0px" align=right>399,254&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=307.6><P style="margin:0px">Gross profit</P>
</TD><TD style="background-color:#CCFFCC" width=67.2><P style="margin:0px" align=right>241,962&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=12><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=67.2><P style="margin:0px" align=right>248,421&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=23.467><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=67.2><P style="margin:0px" align=right>470,863&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=12.4><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=68.933><P style="margin:0px" align=right>475,304&nbsp;</P>
</TD></TR>
<TR><TD width=307.6><P style="margin:0px; text-indent:19.2px">Selling, general and administrative expense</P>
</TD><TD width=67.2><P style="margin:0px" align=right>143,670&nbsp;</P>
</TD><TD width=12><P>&nbsp;</P></TD><TD width=67.2><P style="margin:0px" align=right>146,634&nbsp;</P>
</TD><TD width=23.467><P>&nbsp;</P></TD><TD width=67.2><P style="margin:0px" align=right>283,983&nbsp;</P>
</TD><TD width=12.4><P>&nbsp;</P></TD><TD width=68.933><P style="margin:0px" align=right>286,289&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=307.6><P style="margin:0px; text-indent:19.2px">Research and development expense</P>
</TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=67.2><P style="margin:0px" align=right>42,407&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=12><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=67.2><P style="margin:0px" align=right>42,079&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=23.467><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=67.2><P style="margin:0px" align=right>79,558&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=12.4><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=68.933><P style="margin:0px" align=right>79,568&nbsp;</P>
</TD></TR>
<TR><TD width=307.6><P style="margin:0px">Income from operations</P>
</TD><TD width=67.2><P style="margin:0px" align=right>55,885&nbsp;</P>
</TD><TD width=12><P>&nbsp;</P></TD><TD width=67.2><P style="margin:0px" align=right>59,708&nbsp;</P>
</TD><TD width=23.467><P>&nbsp;</P></TD><TD width=67.2><P style="margin:0px" align=right>107,322&nbsp;</P>
</TD><TD width=12.4><P>&nbsp;</P></TD><TD width=68.933><P style="margin:0px" align=right>109,447&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=307.6><P style="margin:0px; text-indent:19.2px">Interest expense</P>
</TD><TD style="background-color:#CCFFCC" width=67.2><P style="margin:0px" align=right>10,367&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=12><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=67.2><P style="margin:0px" align=right>7,991&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=23.467><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=67.2><P style="margin:0px" align=right>18,174&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=12.4><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=68.933><P style="margin:0px" align=right>15,948&nbsp;</P>
</TD></TR>
<TR><TD width=307.6><P style="margin:0px; text-indent:19.2px">Foreign exchange (gains) losses, net</P>
</TD><TD width=67.2><P style="margin:0px" align=right>2,551&nbsp;</P>
</TD><TD width=12><P>&nbsp;</P></TD><TD width=67.2><P style="margin:0px" align=right>(288)</P>
</TD><TD width=23.467><P>&nbsp;</P></TD><TD width=67.2><P style="margin:0px" align=right>1,777&nbsp;</P>
</TD><TD width=12.4><P>&nbsp;</P></TD><TD width=68.933><P style="margin:0px" align=right>2,305&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=307.6><P style="margin:0px; text-indent:19.2px">Other (income) expense, net</P>
</TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=67.2><P style="margin:0px" align=right>(6,307)</P>
</TD><TD style="background-color:#CCFFCC" width=12><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=67.2><P style="margin:0px" align=right>(3,951)</P>
</TD><TD style="background-color:#CCFFCC" width=23.467><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=67.2><P style="margin:0px" align=right>(5,148)</P>
</TD><TD style="background-color:#CCFFCC" width=12.4><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=68.933><P style="margin:0px" align=right>(4,144)</P>
</TD></TR>
<TR><TD width=307.6><P style="margin:0px">Income before taxes </P>
</TD><TD width=67.2><P style="margin:0px" align=right>49,274&nbsp;</P>
</TD><TD width=12><P>&nbsp;</P></TD><TD width=67.2><P style="margin:0px" align=right>55,956&nbsp;</P>
</TD><TD width=23.467><P>&nbsp;</P></TD><TD width=67.2><P style="margin:0px" align=right>92,519&nbsp;</P>
</TD><TD width=12.4><P>&nbsp;</P></TD><TD width=68.933><P style="margin:0px" align=right>95,338&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=307.6><P style="margin:0px; text-indent:19.2px">Provision for income taxes</P>
</TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=67.2><P style="margin:0px" align=right>(9,974)</P>
</TD><TD style="background-color:#CCFFCC" width=12><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=67.2><P style="margin:0px" align=right>(10,632)</P>
</TD><TD style="background-color:#CCFFCC" width=23.467><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=67.2><P style="margin:0px" align=right>(21,176)</P>
</TD><TD style="background-color:#CCFFCC" width=12.4><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=68.933><P style="margin:0px" align=right>(21,455)</P>
</TD></TR>
<TR><TD width=307.6><P style="margin:0px">Net income including noncontrolling interests</P>
</TD><TD width=67.2><P style="margin:0px" align=right>39,300&nbsp;</P>
</TD><TD width=12><P>&nbsp;</P></TD><TD width=67.2><P style="margin:0px" align=right>45,324&nbsp;</P>
</TD><TD width=23.467><P>&nbsp;</P></TD><TD width=67.2><P style="margin:0px" align=right>71,343&nbsp;</P>
</TD><TD width=12.4><P>&nbsp;</P></TD><TD width=68.933><P style="margin:0px" align=right>73,883&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=307.6><P style="margin:0px; text-indent:19.2px">Less: Net income attributable to </P>
</TD><TD style="background-color:#CCFFCC" width=67.2><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=12><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=67.2><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=23.467><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=67.2><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=12.4><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=68.933><P>&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=307.6><P style="margin:0px; text-indent:28.8px">noncontrolling interests</P>
</TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=67.2><P style="margin:0px" align=right>(1,331)</P>
</TD><TD style="background-color:#CCFFCC" width=12><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=67.2><P style="margin:0px" align=right>(1,926)</P>
</TD><TD style="background-color:#CCFFCC" width=23.467><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=67.2><P style="margin:0px" align=right>(3,109)</P>
</TD><TD style="background-color:#CCFFCC" width=12.4><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=68.933><P style="margin:0px" align=right>(3,990)</P>
</TD></TR>
<TR><TD width=307.6><P style="margin:0px">Net income attributable to Bio-Rad</P>
</TD><TD style="border-bottom:3px double #000000" width=67.2><P style="margin:0px" align=right>$ &nbsp;&nbsp;37,969&nbsp;</P>
</TD><TD width=12><P>&nbsp;</P></TD><TD style="border-bottom:3px double #000000" width=67.2><P style="margin:0px" align=right>$ &nbsp;&nbsp;43,398&nbsp;</P>
</TD><TD width=23.467><P>&nbsp;</P></TD><TD style="border-bottom:3px double #000000" width=67.2><P style="margin:0px" align=right>$ &nbsp;&nbsp;68,234&nbsp;</P>
</TD><TD width=12.4><P>&nbsp;</P></TD><TD style="border-bottom:3px double #000000" width=68.933><P style="margin:0px" align=right>$ &nbsp;69,893&nbsp;</P>
</TD></TR>
<TR><TD width=307.6><P>&nbsp;</P></TD><TD width=67.2><P>&nbsp;</P></TD><TD width=12><P>&nbsp;</P></TD><TD width=67.2><P>&nbsp;</P></TD><TD width=23.467><P>&nbsp;</P></TD><TD width=67.2><P>&nbsp;</P></TD><TD width=12.4><P>&nbsp;</P></TD><TD width=68.933><P>&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=307.6><P style="margin:0px">Basic earnings per share:</P>
</TD><TD style="background-color:#CCFFCC" width=67.2><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=12><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=67.2><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=23.467><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=67.2><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=12.4><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=68.933><P>&nbsp;</P></TD></TR>
<TR><TD width=307.6><P style="margin:0px; text-indent:19.2px">Net income attributable to Bio-Rad</P>
</TD><TD style="border-bottom:3px double #000000" width=67.2><P style="margin:0px" align=right>$ &nbsp;1.39&nbsp;</P>
</TD><TD width=12><P>&nbsp;</P></TD><TD style="border-bottom:3px double #000000" width=67.2><P style="margin:0px" align=right>$ &nbsp;1.61&nbsp;</P>
</TD><TD width=23.467><P>&nbsp;</P></TD><TD style="border-bottom:3px double #000000" width=67.2><P style="margin:0px" align=right>$ &nbsp;2.50&nbsp;</P>
</TD><TD width=12.4><P>&nbsp;</P></TD><TD style="border-bottom:3px double #000000" width=68.933><P style="margin:0px" align=right>$ &nbsp;2.59&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=307.6><P style="margin:0px; text-indent:19.2px">Weighted average common shares</P>
</TD><TD style="background-color:#CCFFCC; border-bottom:3px double #000000" width=67.2><P style="margin:0px" align=right>27,370&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=12><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:3px double #000000" width=67.2><P style="margin:0px" align=right>27,038&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=23.467><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:3px double #000000" width=67.2><P style="margin:0px" align=right>27,346&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=12.4><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:3px double #000000" width=68.933><P style="margin:0px" align=right>26,997&nbsp;</P>
</TD></TR>
<TR><TD width=307.6><P>&nbsp;</P></TD><TD width=67.2><P>&nbsp;</P></TD><TD width=12><P>&nbsp;</P></TD><TD width=67.2><P>&nbsp;</P></TD><TD width=23.467><P>&nbsp;</P></TD><TD width=67.2><P>&nbsp;</P></TD><TD width=12.4><P>&nbsp;</P></TD><TD width=68.933><P>&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=307.6><P style="margin:0px">Diluted earnings per share:</P>
</TD><TD style="background-color:#CCFFCC" width=67.2><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=12><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=67.2><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=23.467><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=67.2><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=12.4><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=68.933><P>&nbsp;</P></TD></TR>
<TR><TD width=307.6><P style="margin:0px; text-indent:19.2px">Net income attributable to Bio-Rad</P>
</TD><TD style="border-bottom:3px double #000000" width=67.2><P style="margin:0px" align=right>$ &nbsp;1.37&nbsp;</P>
</TD><TD width=12><P>&nbsp;</P></TD><TD style="border-bottom:3px double #000000" width=67.2><P style="margin:0px" align=right>$ &nbsp;1.57&nbsp;</P>
</TD><TD width=23.467><P>&nbsp;</P></TD><TD style="border-bottom:3px double #000000" width=67.2><P style="margin:0px" align=right>$ &nbsp;2.47&nbsp;</P>
</TD><TD width=12.4><P>&nbsp;</P></TD><TD style="border-bottom:3px double #000000" width=68.933><P style="margin:0px" align=right>$ &nbsp;2.54&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=307.6><P style="margin:0px; text-indent:19.2px">Weighted average common shares</P>
</TD><TD style="background-color:#CCFFCC; border-bottom:3px double #000000" width=67.2><P style="margin:0px" align=right>27,742&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=12><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:3px double #000000" width=67.2><P style="margin:0px" align=right>27,569&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=23.467><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:3px double #000000" width=67.2><P style="margin:0px" align=right>27,681&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=12.4><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:3px double #000000" width=68.933><P style="margin:0px" align=right>27,553&nbsp;</P>
</TD></TR>
<TR><TD width=626 colspan=8><P>&nbsp;</P></TD></TR>
<TR><TD width=626 colspan=8><P>&nbsp;</P></TD></TR>
<TR><TD width=626 colspan=8><P style="margin:0px" align=center>-4-</P>
</TD></TR>
</TABLE>
<DIV style="width:604.8px"><P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px; page-break-before:always"><BR></P>
</DIV><TABLE style="font-size:10pt" cellspacing=0><TR height=0 style="font-size:0"><TD width=391.667></TD><TD width=16.667></TD><TD width=104.467></TD><TD width=22.333></TD><TD width=108.533></TD></TR>
<TR><TD valign=top width=643.667 colspan=5><P style="margin:0px" align=center>BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=643.667 colspan=5><P style="margin:0px" align=center>Condensed Consolidated Balance Sheets</P>
</TD></TR>
<TR><TD valign=top width=643.667 colspan=5><P style="margin:0px" align=center>(In thousands)</P>
</TD></TR>
<TR><TD valign=top width=643.667 colspan=5><P style="margin:0px" align=center>(Unaudited)</P>
</TD></TR>
<TR><TD valign=top width=391.667><P>&nbsp;</P></TD><TD valign=top width=16.667><P>&nbsp;</P></TD><TD valign=top width=235.333 colspan=3><P>&nbsp;</P></TD></TR>
<TR><TD valign=top width=391.667><P>&nbsp;</P></TD><TD valign=top width=16.667><P>&nbsp;</P></TD><TD valign=top width=235.333 colspan=3><P>&nbsp;</P></TD></TR>
<TR><TD valign=top width=391.667><P>&nbsp;</P></TD><TD valign=top width=16.667><P>&nbsp;</P></TD><TD valign=top width=104.467><P style="margin:0px" align=center>June 30,</P>
</TD><TD valign=top width=22.333><P>&nbsp;</P></TD><TD valign=top width=108.533><P style="margin:0px" align=center>December 31,</P>
</TD></TR>
<TR><TD valign=top width=391.667><P>&nbsp;</P></TD><TD valign=top width=16.667><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=104.467><P style="margin:0px" align=center>2009</P>
</TD><TD valign=top width=22.333><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=108.533><P style="margin:0px" align=center>2008</P>
</TD></TR>
<TR><TD valign=top width=391.667><P>&nbsp;</P></TD><TD valign=top width=16.667><P>&nbsp;</P></TD><TD valign=top width=104.467><P>&nbsp;</P></TD><TD valign=top width=22.333><P>&nbsp;</P></TD><TD valign=top width=108.533><P>&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=391.667><P style="margin:0px">Current assets: </P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=22.333><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P>&nbsp;</P></TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px; padding-left:19.2px">Cash and cash equivalents</P>
</TD><TD valign=top width=16.667><P>&nbsp;</P></TD><TD width=104.467><P style="margin:0px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;533,474&nbsp;</P>
</TD><TD width=22.333><P>&nbsp;</P></TD><TD width=108.533><P style="margin:0px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;204,524&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; padding-left:19.2px">Short-term investments</P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px" align=right>29,885&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px" align=right>38,950&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px; padding-left:19.2px">Accounts receivable, net </P>
</TD><TD valign=top width=16.667><P>&nbsp;</P></TD><TD width=104.467><P style="margin:0px" align=right>335,828&nbsp;</P>
</TD><TD width=22.333><P>&nbsp;</P></TD><TD width=108.533><P style="margin:0px" align=right>339,653&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; padding-left:19.2px">Inventories, net </P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px" align=right>377,594&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px" align=right>375,616&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px; padding-left:19.2px">Other current assets</P>
</TD><TD valign=top width=16.667><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=104.467><P style="margin:0px" align=right>121,054&nbsp;</P>
</TD><TD width=22.333><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=108.533><P style="margin:0px" align=right>135,198&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; text-indent:28.8px">Total current assets </P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px" align=right>1,397,835&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px" align=right>1,093,941&nbsp;</P>
</TD></TR>
<TR><TD width=391.667><P>&nbsp;</P></TD><TD width=16.667><P>&nbsp;</P></TD><TD width=104.467><P>&nbsp;</P></TD><TD width=22.333><P>&nbsp;</P></TD><TD width=108.533><P>&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px">Net property, plant and equipment </P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px" align=right>302,836&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px" align=right>300,732&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px">Goodwill</P>
</TD><TD valign=top width=16.667><P>&nbsp;</P></TD><TD width=104.467><P style="margin:0px" align=right>318,264&nbsp;</P>
</TD><TD width=22.333><P>&nbsp;</P></TD><TD width=108.533><P style="margin:0px" align=right>321,820&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px">Purchased intangibles, net</P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px" align=right>213,933&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px" align=right>228,590&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px">Other assets</P>
</TD><TD valign=top width=16.667><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=104.467><P style="margin:0px" align=right>111,589&nbsp;</P>
</TD><TD width=22.333><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=108.533><P style="margin:0px" align=right>92,181&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; text-indent:28.8px">Total assets</P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:3px double #000000" width=104.467><P style="margin:0px" align=right>$ &nbsp;&nbsp;2,344,457&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:3px double #000000" width=108.533><P style="margin:0px" align=right>$ &nbsp;&nbsp;2,037,264&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P>&nbsp;</P></TD><TD valign=top width=16.667><P>&nbsp;</P></TD><TD valign=top width=104.467><P>&nbsp;</P></TD><TD valign=top width=22.333><P>&nbsp;</P></TD><TD valign=top width=108.533><P>&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=391.667><P style="margin:0px">Current liabilities:</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=22.333><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P>&nbsp;</P></TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px; padding-left:19.2px">Notes payable and current maturities of long-term debt</P>
</TD><TD valign=top width=16.667><P>&nbsp;</P></TD><TD valign=top width=104.467><P style="margin:0px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5,874&nbsp;</P>
</TD><TD valign=top width=22.333><P>&nbsp;</P></TD><TD valign=top width=108.533><P style="margin:0px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9,578&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; padding-left:19.2px">Accounts payable</P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px" align=right>90,850&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px" align=right>117,982&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px; padding-left:19.2px">Accrued payroll and employee benefits</P>
</TD><TD valign=top width=16.667><P>&nbsp;</P></TD><TD width=104.467><P style="margin:0px" align=right>104,267&nbsp;</P>
</TD><TD width=22.333><P>&nbsp;</P></TD><TD width=108.533><P style="margin:0px" align=right>119,420&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; padding-left:19.2px">Sales, income and other taxes payable</P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px" align=right>46,486&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px" align=right>33,731&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px; padding-left:19.2px">Other current liabilities</P>
</TD><TD valign=top width=16.667><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=104.467><P style="margin:0px" align=right>136,132&nbsp;</P>
</TD><TD width=22.333><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=108.533><P style="margin:0px" align=right>137,323&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; text-indent:28.8px">Total current liabilities</P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px" align=right>383,609&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px" align=right>418,034&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P>&nbsp;</P></TD><TD valign=top width=16.667><P>&nbsp;</P></TD><TD width=104.467><P>&nbsp;</P></TD><TD width=22.333><P>&nbsp;</P></TD><TD width=108.533><P>&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=391.667><P style="margin:0px">Long-term debt, net of current maturities</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px" align=right>738,454&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px" align=right>445,979&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px">Other long-term liabilities</P>
</TD><TD valign=top width=16.667><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=104.467><P style="margin:0px" align=right>94,753&nbsp;</P>
</TD><TD width=22.333><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=108.533><P style="margin:0px" align=right>102,611&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; text-indent:28.8px">Total liabilities</P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px" align=right>1,216,816&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px" align=right>966,624&nbsp;</P>
</TD></TR>
<TR><TD valign=bottom width=391.667><P>&nbsp;</P></TD><TD valign=bottom width=16.667><P>&nbsp;</P></TD><TD valign=bottom width=104.467><P>&nbsp;</P></TD><TD valign=bottom width=22.333><P>&nbsp;</P></TD><TD valign=bottom width=108.533><P>&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=391.667><P style="margin:0px">Bio-Rad stockholders&#146;equity</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px" align=right>1,110,181&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px" align=right>1,041,139&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px">Noncontrolling interests</P>
</TD><TD valign=top width=16.667><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=104.467><P style="margin:0px" align=right>17,460&nbsp;</P>
</TD><TD width=22.333><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=108.533><P style="margin:0px" align=right>29,501&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=391.667><P style="margin:0px; text-indent:28.8px">Total stockholders&#146; equity</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=104.467><P style="margin:0px" align=right>1,127,641</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=108.533><P style="margin:0px" align=right>1,070,640&nbsp;</P>
</TD></TR>
<TR><TD width=391.667><P style="margin:0px; text-indent:28.8px">Total liabilities and stockholders&#146; equity</P>
</TD><TD width=16.667><P>&nbsp;</P></TD><TD style="border-bottom:3px double #000000" width=104.467><P style="margin:0px" align=right>$ &nbsp;&nbsp;2,344,457</P>
</TD><TD width=22.333><P>&nbsp;</P></TD><TD style="border-bottom:3px double #000000" width=108.533><P style="margin:0px" align=right>$ &nbsp;&nbsp;2,037,264&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P>&nbsp;</P></TD><TD valign=top width=16.667><P>&nbsp;</P></TD><TD valign=top width=104.467><P>&nbsp;</P></TD><TD valign=top width=22.333><P>&nbsp;</P></TD><TD valign=top width=108.533><P>&nbsp;</P></TD></TR>
<TR><TD valign=top width=391.667><P>&nbsp;</P></TD><TD valign=top width=16.667><P>&nbsp;</P></TD><TD valign=top width=104.467><P>&nbsp;</P></TD><TD valign=top width=22.333><P>&nbsp;</P></TD><TD valign=top width=108.533><P>&nbsp;</P></TD></TR>
<TR><TD valign=top width=643.667 colspan=5><P style="margin:0px" align=center>-5-</P>
</TD></TR>
</TABLE>
<DIV style="width:604.8px"><P style="margin-top:0px; margin-bottom:6px"><BR></P>
<P style="margin-top:0px; margin-bottom:6px"><BR>
<BR></P>
<P style="margin-top:0px; margin-bottom:6px; page-break-before:always"><BR></P>
</DIV><TABLE style="font-size:10pt" cellspacing=0><TR height=0 style="font-size:0"><TD width=439.667></TD><TD width=82.267></TD><TD width=16.667></TD><TD width=81.067></TD></TR>
<TR><TD valign=top width=619.667 colspan=4><P style="line-height:10pt; margin:0px" align=center>BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=619.667 colspan=4><P style="line-height:10pt; margin:0px" align=center>Condensed Consolidated Statements of Cash Flows</P>
</TD></TR>
<TR><TD valign=top width=619.667 colspan=4><P style="line-height:10pt; margin:0px" align=center>(In thousands)</P>
</TD></TR>
<TR><TD valign=top width=619.667 colspan=4><P style="line-height:10pt; margin:0px" align=center>(Unaudited) &nbsp;</P>
</TD></TR>
<TR><TD valign=top width=439.667><P>&nbsp;</P></TD><TD valign=top width=180 colspan=3><P>&nbsp;</P></TD></TR>
<TR><TD valign=top width=439.667><P>&nbsp;</P></TD><TD valign=top width=180 colspan=3><P style="line-height:10pt; margin:0px" align=center>Six Months Ended </P>
</TD></TR>
<TR><TD valign=top width=439.667><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=180 colspan=3><P style="line-height:10pt; margin:0px" align=center>June 30,</P>
</TD></TR>
<TR><TD valign=top width=439.667><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=82.267><P style="line-height:10pt; margin:0px" align=center>2009&nbsp;</P>
</TD><TD valign=top width=16.667><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=81.067><P style="line-height:10pt; margin:0px" align=center>2008&nbsp;</P>
</TD></TR>
<TR><TD width=439.667><P>&nbsp;</P></TD><TD width=82.267><P>&nbsp;</P></TD><TD width=16.667><P>&nbsp;</P></TD><TD width=81.067><P>&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=439.667><P style="margin-top:0px; margin-bottom:1.133px">Cash flows from operating activities:</P>
</TD><TD style="background-color:#CCFFCC" width=82.267><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=81.067><P>&nbsp;</P></TD></TR>
<TR><TD width=439.667><P style="margin-top:0px; margin-bottom:1.133px; padding-left:19.2px">Cash received from customers</P>
</TD><TD width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;831,208&nbsp;</P>
</TD><TD width=16.667><P>&nbsp;</P></TD><TD width=81.067><P style="margin-top:0px; margin-bottom:1.133px" align=right>$ &nbsp;&nbsp;877,910&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=439.667><P style="margin-top:0px; margin-bottom:1.133px; padding-left:19.2px">Cash paid to suppliers and employees</P>
</TD><TD style="background-color:#CCFFCC" width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>(698,527)</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=81.067><P style="margin-top:0px; margin-bottom:1.133px" align=right>(781,755)</P>
</TD></TR>
<TR><TD width=439.667><P style="margin-top:0px; margin-bottom:1.133px; padding-left:19.2px">Interest paid</P>
</TD><TD width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>(15,340)</P>
</TD><TD width=16.667><P>&nbsp;</P></TD><TD width=81.067><P style="margin-top:0px; margin-bottom:1.133px" align=right>(15,448)</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=439.667><P style="margin-top:0px; margin-bottom:1.133px; padding-left:19.2px">Income tax payments</P>
</TD><TD style="background-color:#CCFFCC" width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>(13,220)</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=81.067><P style="margin-top:0px; margin-bottom:1.133px" align=right>(16,848)</P>
</TD></TR>
<TR><TD width=439.667><P style="margin-top:0px; margin-bottom:1.133px; padding-left:19.2px">Other operating activities</P>
</TD><TD style="border-bottom:1px solid #000000" width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>7,742&nbsp;</P>
</TD><TD width=16.667><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=81.067><P style="margin-top:0px; margin-bottom:1.133px" align=right>3,052&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=439.667><P style="margin-top:0px; margin-bottom:1.133px; padding-left:19.2px">Net cash provided by operating activities</P>
</TD><TD style="background-color:#CCFFCC" width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>111,863&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=81.067><P style="margin-top:0px; margin-bottom:1.133px" align=right>66,911&nbsp;</P>
</TD></TR>
<TR><TD width=439.667><P>&nbsp;</P></TD><TD width=82.267><P>&nbsp;</P></TD><TD width=16.667><P>&nbsp;</P></TD><TD width=81.067><P>&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=439.667><P style="margin-top:0px; margin-bottom:1.133px">Cash flows from investing activities:</P>
</TD><TD style="background-color:#CCFFCC" width=82.267><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=81.067><P>&nbsp;</P></TD></TR>
<TR><TD width=439.667><P style="margin-top:0px; margin-bottom:1.133px; padding-left:19.2px">Payments for acquisitions and long-term investments</P>
</TD><TD width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>(33,805)</P>
</TD><TD width=16.667><P>&nbsp;</P></TD><TD width=81.067><P style="margin-top:0px; margin-bottom:1.133px" align=right>(17,110)</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=439.667><P style="margin-top:0px; margin-bottom:1.133px; padding-left:19.2px">Other investing activities</P>
</TD><TD style="background-color:#CCFFCC" width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>(36,965)</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=81.067><P style="margin-top:0px; margin-bottom:1.133px" align=right>(35,043)</P>
</TD></TR>
<TR><TD width=439.667><P style="margin:0px; padding-left:19.2px">Net cash used in investing activities</P>
</TD><TD style="border-top:1px solid #000000" width=82.267><P style="margin:0px" align=right>(70,770)</P>
</TD><TD width=16.667><P>&nbsp;</P></TD><TD style="border-top:1px solid #000000" width=81.067><P style="margin:0px" align=right>(52,153)</P>
</TD></TR>
<TR><TD width=439.667><P>&nbsp;</P></TD><TD width=82.267><P>&nbsp;</P></TD><TD width=16.667><P>&nbsp;</P></TD><TD width=81.067><P>&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=439.667><P style="margin-top:0px; margin-bottom:1.133px">Cash flows from financing activities:</P>
</TD><TD style="background-color:#CCFFCC" width=82.267><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=81.067><P>&nbsp;</P></TD></TR>
<TR><TD width=439.667><P style="margin-top:0px; margin-bottom:1.133px; padding-left:19.2px">Payments on long-term debt</P>
</TD><TD width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>(3,585)</P>
</TD><TD width=16.667><P>&nbsp;</P></TD><TD width=81.067><P style="margin:0px" align=right>(4,414)</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=439.667><P style="margin-top:0px; margin-bottom:1.133px; padding-left:19.2px">Long-term borrowings</P>
</TD><TD style="background-color:#CCFFCC" width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>294,750&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=81.067><P style="margin-top:0px; margin-bottom:1.133px" align=right>--&nbsp;</P>
</TD></TR>
<TR><TD width=439.667><P style="margin-top:0px; margin-bottom:1.133px; padding-left:19.2px">Other financing activities</P>
</TD><TD style="border-bottom:1px solid #000000" width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>(60)</P>
</TD><TD width=16.667><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=81.067><P style="margin-top:0px; margin-bottom:1.133px" align=right>8,090&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=439.667><P style="margin-top:0px; margin-bottom:1.133px; padding-left:19.2px">Net cash provided by financing activities</P>
</TD><TD style="background-color:#CCFFCC" width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>291,105&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=81.067><P style="margin-top:0px; margin-bottom:1.133px" align=right>3,676&nbsp;</P>
</TD></TR>
<TR><TD width=439.667><P>&nbsp;</P></TD><TD width=82.267><P>&nbsp;</P></TD><TD width=16.667><P>&nbsp;</P></TD><TD width=81.067><P>&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=439.667><P style="margin-top:0px; margin-bottom:1.133px">Effect of exchange rate changes on cash</P>
</TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>(3,248)</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=81.067><P style="margin-top:0px; margin-bottom:1.133px" align=right>3,445&nbsp;</P>
</TD></TR>
<TR><TD width=439.667><P>&nbsp;</P></TD><TD width=82.267><P>&nbsp;</P></TD><TD width=16.667><P>&nbsp;</P></TD><TD width=81.067><P>&nbsp;</P></TD></TR>
<TR><TD width=439.667><P style="margin-top:0px; margin-bottom:1.133px">Net increase in cash and cash equivalents</P>
</TD><TD width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>328,950&nbsp;</P>
</TD><TD width=16.667><P>&nbsp;</P></TD><TD width=81.067><P style="margin-top:0px; margin-bottom:1.133px" align=right>21,879&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=439.667><P style="margin-top:0px; margin-bottom:1.133px">Cash and cash equivalents at beginning of period</P>
</TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>204,524&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=81.067><P style="margin-top:0px; margin-bottom:1.133px" align=right>161,764&nbsp;</P>
</TD></TR>
<TR><TD width=439.667><P style="margin-top:0px; margin-bottom:1.133px">Cash and cash equivalents at end of period</P>
</TD><TD style="border-bottom:3px double #000000" width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;533,474&nbsp;</P>
</TD><TD width=16.667><P>&nbsp;</P></TD><TD style="border-bottom:3px double #000000" width=81.067><P style="margin-top:0px; margin-bottom:1.133px" align=right>$ &nbsp;&nbsp;183,643&nbsp;</P>
</TD></TR>
<TR><TD width=439.667><P>&nbsp;</P></TD><TD width=82.267><P>&nbsp;</P></TD><TD width=16.667><P>&nbsp;</P></TD><TD width=81.067><P>&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=439.667><P style="margin:0px">Reconciliation of net income including noncontrolling interests to </P>
</TD><TD style="background-color:#CCFFCC" width=82.267><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=81.067><P>&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=439.667><P style="margin:0px; text-indent:19.2px">net cash provided by operating activities:</P>
</TD><TD style="background-color:#CCFFCC" width=82.267><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=81.067><P>&nbsp;</P></TD></TR>
<TR><TD width=439.667><P>&nbsp;</P></TD><TD width=82.267><P>&nbsp;</P></TD><TD width=16.667><P>&nbsp;</P></TD><TD width=81.067><P>&nbsp;</P></TD></TR>
<TR><TD width=439.667><P style="margin:0px; text-indent:9.6px">Net income including noncontrolling interests </P>
</TD><TD width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;71,343&nbsp;</P>
</TD><TD width=16.667><P>&nbsp;</P></TD><TD width=81.067><P style="margin-top:0px; margin-bottom:1.133px" align=right>$ &nbsp;&nbsp;&nbsp;73,883&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=439.667><P style="margin-top:0px; margin-bottom:1.133px; text-indent:9.6px">Adjustments to reconcile net income including noncontrolling interests </P>
</TD><TD style="background-color:#CCFFCC" width=82.267><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=81.067><P>&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=439.667><P style="margin-top:0px; margin-bottom:1.133px; text-indent:28.8px">to net cash provided by operating activities:</P>
</TD><TD style="background-color:#CCFFCC" width=82.267><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=81.067><P>&nbsp;</P></TD></TR>
<TR><TD width=439.667><P style="margin-top:0px; margin-bottom:1.133px; text-indent:28.8px">Depreciation and amortization</P>
</TD><TD width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>47,765&nbsp;</P>
</TD><TD width=16.667><P>&nbsp;</P></TD><TD width=81.067><P style="margin-top:0px; margin-bottom:1.133px" align=right>49,323&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=439.667><P style="margin-top:0px; margin-bottom:1.133px; text-indent:28.8px">Changes in working capital</P>
</TD><TD style="background-color:#CCFFCC" width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>(7,490)</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=81.067><P style="margin-top:0px; margin-bottom:1.133px" align=right>(61,270)</P>
</TD></TR>
<TR><TD width=439.667><P style="margin-top:0px; margin-bottom:1.133px; text-indent:28.8px">Other</P>
</TD><TD style="border-bottom:1px solid #000000" width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>245&nbsp;</P>
</TD><TD width=16.667><P>&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=81.067><P style="margin-top:0px; margin-bottom:1.133px" align=right>4,975</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=439.667><P style="margin-top:0px; margin-bottom:1.133px">Net cash provided by operating activities</P>
</TD><TD style="background-color:#CCFFCC; border-bottom:3px double #000000" width=82.267><P style="margin-top:0px; margin-bottom:1.133px" align=right>$ &nbsp;&nbsp;&nbsp;111,863&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P>&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:3px double #000000" width=81.067><P style="margin-top:0px; margin-bottom:1.133px" align=right>$ &nbsp;&nbsp;&nbsp;66,911&nbsp;</P>
</TD></TR>
<TR><TD width=439.667><P>&nbsp;</P></TD><TD width=82.267><P>&nbsp;</P></TD><TD width=16.667><P>&nbsp;</P></TD><TD width=81.067><P>&nbsp;</P></TD></TR>
<TR><TD width=521.933 colspan=2><P>&nbsp;</P></TD><TD width=16.667><P>&nbsp;</P></TD><TD width=81.067><P>&nbsp;</P></TD></TR>
<TR><TD width=521.933 colspan=2><P>&nbsp;</P></TD><TD width=16.667><P>&nbsp;</P></TD><TD width=81.067><P>&nbsp;</P></TD></TR>
<TR><TD width=521.933 colspan=2><P>&nbsp;</P></TD><TD width=16.667><P>&nbsp;</P></TD><TD width=81.067><P>&nbsp;</P></TD></TR>
<TR><TD width=619.667 colspan=4><P style="line-height:11pt; margin:0px" align=center>-6-</P>
</TD></TR>
</TABLE>
<DIV style="width:604.8px"><P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
</DIV></BODY>
<!-- EDGAR Validation Code: 2D7C6E73 -->
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
